Oppenheimer Reiterates Outperform Rating on Jasper Therapeutics (JSPR)

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $80.00 price target on Jasper Therapeutics (NASDAQ: JSPR).

The analyst commented: "We anticipate the imminent initial readout from BEACON, a study of briquilimab in CSU expected during the week of 01/06/2025 and share our latest thoughts heading into this key catalyst. As updated in 3Q, the dataset should include all dose cohorts from the Ph1b/2a study up through 240mg with investor focus on UAS7 at week-12 and preliminary safety profile (Exhibit 1). We view the upside scenario as briquilimab showing comparable efficacy (primarily UAS7) and signs of superior preliminary safety profile compared to barzolvolimab. Our scenario analysis for JSPR shares upon BEACON readout forecasts +83% probability-adj. upside (Exhibit 2), potentially narrowing the current valuation gap between JSPR (~$310M) and CLDX (~$1.7B), while subsequent development could narrow the timing gap to 12-18 months vs. CLDX."

For an analyst ratings summary and ratings history on Jasper Therapeutics click here. For more ratings news on Jasper Therapeutics click here.

Shares of Jasper Therapeutics closed at $21.38 yesterday.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• iQSTEL restructures corporate entities in internal realignment
• Ideal Power (IPWR) files $75M mixed shelf